13F Holdings
中文EN

MBRX Moleculin Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1659617 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY79.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-55.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio1.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.37x
Accruals ratio76.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$15.89M$17.73M$19.49M$18.97M$14.42M
SG&A expense$9.12M$8.79M$10.02M$11.54M$8.39M
Operating income-$25.10M-$26.64M-$29.63M-$30.64M-$22.97M
Pretax income-$33.56M-$26.05M———
Income tax$0$0$0$0$0
Net income-$33.56M-$26.05M-$29.77M-$29.02M-$15.89M
EBITDA-$25.01M-$26.52M-$29.50M-$30.51M-$22.80M
EPS (basic)-28.42-189.14-15.07-15.22-0.59
EPS (diluted)————-0.59
Weighted avg. shares (diluted)————26.88M
Banking
Net interest income———$240,000$306,000
Balance sheet
Cash & equivalents$8.88M$4.28M$23.55M$43.15M$70.90M
Current assets$9.69M$5.19M$26.27M$45.60M$72.50M
PP&E, net$78,000$159,000$272,000$275,000$338,000
Total assets$22.13M$16.93M$38.22M$57.42M$84.09M
Current liabilities$6.85M$5.36M$6.82M$4.82M$3.62M
Total liabilities$7.12M$5.72M$12.14M$5.23M$5.10M
Shareholders' equity$15.01M$11.21M$30.93M$52.19M$78.99M
Shares outstanding159,961135,1552.23M1.91M28.58M
Cash flow statement
Operating cash flow-$22.73M-$23.86M-$23.59M-$27.64M-$18.95M
Capital expenditure$0$13,000$124,000$67,000$19,000
Free cash flow-$22.73M-$23.88M-$23.71M-$27.71M-$18.97M
Investing cash flow$0-$13,000-$124,000-$67,000-$19,000
Financing cash flow$27.28M$4.63M$4.14M-$23,000$74.72M
Depreciation & amortization$90,000$126,000$127,000$130,000$164,000
Stock-based compensation$1.66M$1.73M$1.98M$2.27M$2.37M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.